CURRENT MEDICATIONS OVERVIEW,,
MEDICATION,GENE(S),PRESCRIBING CONSIDERATIONS BASED ON myDNA TEST
"Moclobemide",CYP2C19,"Minor – result should be considered as may affect medicationresponse"
"Quetiapine",CYP3A4,Usual prescribing considerations apply
MEDICATIONS THAT DO NOT HAVE PRESCRIBING CONSIDERATIONS BASED ON myDNA TEST,,
"clonazepam, liothyronine, lorazepam, oxazepam, progesterone",,
MEDICATIONS WITH MAJOR PRESCRIBING CONSIDERATIONS,,,,
DRUG CATEGORY,MEDICATION,"GENE(S)INVOLVED",POTENTIAL CLINICAL ISSUES,"PUBLISHEDGUIDELINES"
Anticoagulants,Acenocoumarol,"VKORC1CYP2C9","Significantly increasedacenocoumarol sensitivity",DPWG
"",Warfarin,"VKORC1CYP2C9","Significantly increased warfarinsensitivity",FDA1
Antiepileptics,Phenytoin,CYP2C9,Adverse effects,CPIC2
Antiplatelet drugs,Clopidogrel,CYP2C19,Reduced / inadequate response,CPIC3
Statins,Simvastatin,"SLCO1B1CYP3A4",Adverse effects,CPIC4
MEDICATIONS WITH MINOR PRESCRIBING CONSIDERATIONS,,,,
DRUG CATEGORY,MEDICATION,"GENE(S)INVOLVED",POTENTIAL CLINICAL ISSUES,"PUBLISHEDGUIDELINES"
"ADHD -miscellaneous agents",Atomoxetine,CYP2D6,Adverse effects,-
"Angiotensin receptorblockers",Irbesartan,CYP2C9,"Increased therapeutic and/oradverse effects",-
Losartan,CYP2C9,Reduced / inadequate response,-,
MEDICATIONS WITH MINOR PRESCRIBING CONSIDERATIONS,,,,
DRUG CATEGORY,MEDICATION,"GENE(S)INVOLVED",POTENTIAL CLINICAL ISSUES,"PUBLISHEDGUIDELINES"
Antiarrhythmics,Flecainide,CYP2D6,Adverse effects,DPWG5
"",Propafenone,CYP2D6,Adverse effects,DPWG5
"Antidepressants -other",Mirtazapine,"CYP2D6CYP1A2",Altered response,-
"",Moclobemide,CYP2C19,Adverse effects,-
"Antidepressants -serotoninnoradrenalinereuptake inhibitors",Duloxetine,"CYP2D6CYP1A2",Reduced / inadequate response,-
"",Venlafaxine,CYP2D6,Adverse effects,DPWG5
"Antidepressants -SSRIs",Citalopram,CYP2C19,Adverse effects,CPIC6
"",Escitalopram,CYP2C19,Adverse effects,CPIC6
"",Fluoxetine,"CYP2D6CYP2C9",Altered response,-
"",Paroxetine,CYP2D6,Adverse effects,CPIC6
"",Sertraline,CYP2C19,Adverse effects,CPIC6
"Antidepressants -tricyclicantidepressants",Amitriptyline,"CYP2D6CYP2C19",Altered response,CPIC7
"",Clomipramine,"CYP2D6CYP2C19",Altered response,CPIC7
"",Desipramine,CYP2D6,Adverse effects,CPIC7
"",Doxepin,"CYP2D6CYP2C19",Altered response,CPIC7
"",Imipramine,"CYP2D6CYP2C19",Altered response,CPIC7
"",Nortriptyline,CYP2D6,Adverse effects,CPIC7
Antidiabetics,Gliclazide,"CYP2C9CYP2C19","Increased therapeutic and/oradverse effects",-
"",Glimepiride,CYP2C9,"Increased therapeutic and/oradverse effects",-
"",Glyburide,CYP2C9,"Increased therapeutic and/oradverse effects",-
Antiemetics,Ondansetron,CYP2D6,"Increased therapeutic and/oradverse effects",CPIC8
Antifungals - Azoles,Voriconazole,CYP2C19,"Increased therapeutic and/oradverse effects",CPIC9
Antihistamines,Chlorpheniramine,CYP2D6,Adverse effects,-
"",Dexchlorpheniramine,CYP2D6,Adverse effects,-
Antipsychotics,Aripiprazole,CYP2D6,Adverse effects,-
"",Brexpiprazole,CYP2D6,Adverse effects,-
"",Clozapine,CYP1A2,Reduced / inadequate response,-
"",Haloperidol,CYP2D6,Adverse effects,-
"",Olanzapine,CYP1A2,Reduced / inadequate response,-
"",Pimozide,CYP2D6,Adverse effects,
"",Risperidone,CYP2D6,Adverse effects,DPWG5
"",Zuclopenthixol,CYP2D6,Adverse effects,DPWG5
Antitussives,Dextromethorphan,CYP2D6,Altered response,-
Benzodiazepines,Clobazam,CYP2C19,Adverse effects,-
"",Diazepam,CYP2C19,Adverse effects,-
Beta blockers,Metoprolol,CYP2D6,Adverse effects,DPWG5
"",Propranolol,"CYP2D6CYP1A2",Altered response,-
Hypnotics,Melatonin,CYP1A2,Reduced / inadequate response,-
MEDICATIONS WITH MINOR PRESCRIBING CONSIDERATIONS,,,,
DRUG CATEGORY,MEDICATION,"GENE(S)INVOLVED",POTENTIAL CLINICAL ISSUES,"PUBLISHEDGUIDELINES"
"Immunomodulatorsand antineoplastics",Tamoxifen,CYP2D6,Reduced / inadequate response,CPIC10
Miscellaneous,Cyclophosphamide,CYP2C19,Reduced / inadequate response,-
"",Eliglustat,CYP2D6,Adverse effects,TGA11
"",Naltrexone,OPRM1,"Associated with reducedresponse to naltrexone",
"",Proguanil,CYP2C19,Reduced / inadequate response,-
Neurological drugs,Tetrabenazine,CYP2D6,Adverse effects,FDA12
NSAIDs,Celecoxib,CYP2C9,"Increased therapeutic and/oradverse effects",-
"",Diclofenac,CYP2C9,Adverse effects,-
"",Flurbiprofen,CYP2C9,Adverse effects,-
"",Ibuprofen,CYP2C9,Adverse effects,-
"",Indomethacin,CYP2C9,Adverse effects,-
"",Mefenamic Acid,CYP2C9,Adverse effects,-
"",Meloxicam,CYP2C9,Adverse effects,-
"",Piroxicam,CYP2C9,Adverse effects,-
Opioid Analgesics,Morphine,OPRM1,"Associated with increasedtherapeutic and/or adverseeffects to morphine",-
"Proton pumpinhibitors",Dexlansoprazole,CYP2C19,"Increased therapeutic and/oradverse effects",FDA13
"",Esomeprazole,CYP2C19,"Increased therapeutic and/oradverse effects",-
"",Lansoprazole,CYP2C19,"Increased therapeutic and/oradverse effects",-
"",Omeprazole,CYP2C19,"Increased therapeutic and/oradverse effects",-
"",Pantoprazole,CYP2C19,"Increased therapeutic and/oradverse effects",-
"",Rabeprazole,CYP2C19,"Increased therapeutic and/oradverse effects",-
Statins,Atorvastatin,"SLCO1B1CYP3A4",Adverse effects,-
Fluvastatin,"SLCO1B1CYP2C9","Increased therapeutic and/oradverse effects",-,
MEDICATIONS WITH USUAL PRESCRIBING CONSIDERATIONS,,,,
DRUG CATEGORY,MEDICATION,"GENE(S)INVOLVED",POTENTIAL CLINICAL ISSUES,"PUBLISHEDGUIDELINES"
"Anticholinergics(genitourinary)",Darifenacin,CYP2D6,"No altered effect predicted bygenotype",-
"",Fesoterodine,CYP2D6,"No altered effect predicted bygenotype",-
"",Tolterodine,CYP2D6,"No altered effect predicted bygenotype",-
Anticholinesterases,Donepezil,CYP2D6,"No altered effect predicted bygenotype",-
"",Galantamine,CYP2D6,"No altered effect predicted bygenotype",-
"Antidepressants -other",Vortioxetine,CYP2D6,"No altered effect predicted bygenotype",-
MEDICATIONS WITH USUAL PRESCRIBING CONSIDERATIONS,,,,
DRUG CATEGORY,MEDICATION,"GENE(S)INVOLVED",POTENTIAL CLINICAL ISSUES,"PUBLISHEDGUIDELINES"
"Antidepressants -SSRIs",Fluvoxamine,"CYP2D6CYP1A2","No altered effect predicted bygenotype",CPIC6
Antiemetics,Metoclopramide,CYP2D6,"No altered effect predicted bygenotype",-
Antihistamines,Promethazine,CYP2D6,Adverse effects,-
Antipsychotics,Chlorpromazine,CYP2D6,"No altered effect predicted bygenotype",-
"",Quetiapine,CYP3A4,"No altered effect predicted bygenotype",-
Beta blockers,Carvedilol,CYP2D6,"No altered effect predicted bygenotype",-
"",Nebivolol,CYP2D6,"No altered effect predicted bygenotype",-
Calcineurin inhibitors,Tacrolimus,CYP3A5,"No altered effect predicted bygenotype",CPIC14
"Glaucoma - ocularpreparations",Timolol,CYP2D6,"No altered effect predicted bygenotype",-
Miscellaneous,Atazanavir,CYP3A5,"No altered effect predicted bygenotype",-
Opioid Analgesics,Codeine,"CYP2D6OPRM1","Associated with increasedsensitivity to codeine",CPIC15
"",Hydrocodone,CYP2D6,"No altered effect predicted bygenotype",
"",Oxycodone,CYP2D6,"No altered effect predicted bygenotype",DPWG5
"",Tramadol,CYP2D6,"No altered effect predicted bygenotype",DPWG5
Psychostimulants,Dextroamphetamine,CYP2D6,"No altered effect predicted bygenotype",-
"",Lisdexamfetamine,CYP2D6,"No altered effect predicted bygenotype",-
Statins,Pravastatin,SLCO1B1,"No altered effect predicted bygenotype",-
Rosuvastatin,SLCO1B1,"No altered effect predicted bygenotype",-,
